---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-22-000023"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2022-01-28T23:59:59+00:00"
generated_at: "2026-06-27T14:22:04.803731+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Xeris files Strongbridge unaudited 9M 2021 financials: net loss $31.6M, rev $29.9M

## Summary
- Strongbridge nine months ended Sep 30, 2021: net loss $31.6M vs $33.1M prior-year.
- Revenue $29.9M vs $22.5M prior-year, primarily from Keveyis sales.
- Cash and equivalents $55.3M; accumulated deficit $337.2M as of Sep 30, 2021.
- Acquisition by Xeris closed Oct 5, 2021; filing satisfies SEC requirement for acquired company financial statements.

## SEC filing metadata
- accession: 0001867096-22-000023
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2022-01-28T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000023/0001867096-22-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000023/xers-20220128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-22-000023
- JSON: https://secwatch.observer/filing/0001867096-22-000023.json
- Plain text: https://secwatch.observer/filing/0001867096-22-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.